|
COVID-19 Vaccine Safety and Efficacy in Systemic Lupus Erythematosus: A Systematic Review 1.Faculty of Medicine, Universitas Sebelas Maret, Ir Sutami Street No 36, Kentingan, Jebres, Surakarta, Indonesia, 57126 Abstract SLE is a kind of autoimmune rheumatic illness that can range in severity and organ involvement. Immune dysregulation is a feature of SLE, which is exacerbated by immunosuppressive drugs. Most live vaccines are contraindicated in SLE, and inactivated vaccines must be given before immunosuppression. Therefore, this paper aims to review COVID-19 vaccine safety and efficacy in Systemic Lupus Erythematosus. We systematically searched Pubmed, Cochrane, and Scopus for peer-reviewed studies examining the COVID-19 vaccine safety and efficacy in Systemic Lupus Erythematosus. The research included in this review was a study from 2000 to 2022, the full text of the article can be obtained, and the patient^s age is over 18 years. Three reviewers independently extracted data on relevant clinical outcomes, trial characteristics, and patient characteristics and used the Cochrane Risk of Bias Assessment Tool. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation. COVID-19 vaccinations tend to be safe in SLE patients, whereas mRNA vaccines cause more significant local responses. The adverse effects were mildlocal soreness, weariness, and a headache. The chances of a significant lupus flare are slim. COVID-19 immunisation is less efficient than in the general population, especially in individuals on immunosuppressive medications or using inactivated vaccines. Keywords: COVID-19 Vaccine, Safety, Efficacy, Systemic Lupus Erythematosus Topic: Biomedical Science |
| ICoLiST 2022 Conference | Conference Management System |